NEW YORK, Oct. 18, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery

http://www.reportlinker.com/p0739472/United-States-Diabetes-Care-Devices...

United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery

Summary

GlobalData's new report, "United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery" provides key market data on the United States Diabetes Care Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories – Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for Diabetes Care Devices market categories – Glucose Monitoring and Insulin Delivery.

- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within two market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the two market categories.

- Global corporate-level profiles of key companies operating within the United States Diabetes Care Devicesmarket.

- Key players covered include LifeScan, Inc., Medtronic, Inc., Bayer HealthCare AG, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.

- Develop market-entry and market expansion strategies.

- Design competition strategies by identifying who-stands-where in the United States Diabetes Care Devices competitive landscape.

- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.

- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 11

2.1 What is This Report About? 11

3 Diabetes Care Devices In United States 12

3.1 Diabetes Care Devices, Market Segmentation 12

3.2 Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018 13

3.3 Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011 14

3.4 Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15

3.5 Diabetes Care Devices, United States, Company Share (2010-2011) 22

4 Glucose Monitoring In United States 24

4.1 Glucose Monitoring, Market Segmentation 24

4.2 Glucose Monitoring Market, United States, Revenue Mix ($m), 2011 25

4.3 Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26

4.4 Glucose Monitoring Overall Revenue, (2004-2018) 27

4.4.1 Blood Glucose Meters, Revenue (2004-2018) 31

4.5 Glucose Monitoring Overall Volume (2004-2018) 35

4.5.1 Blood Glucose Meters, Volume (2004-2018) 39

4.6 Glucose Monitoring Average Price (2004-2018) 43

4.7 Glucose Monitoring Distribution Share (2010-2011) 44

4.8 Glucose Monitoring, United States, Company Share (2010-2011) 45

5 Insulin Delivery In United States 47

5.1 Insulin Delivery Market, United States, Revenue Mix ($m), 2011 48

5.2 Insulin Delivery Market, United States, Segment Contribution (%), 2011 49

5.3 Insulin Delivery Overall Revenue, (2004-2018) 50

5.3.1 Insulin Pens, Revenue (2004-2018) 54

5.3.2 Insulin Pumps, Revenue (2004-2018) 58

5.4 Insulin Delivery Overall Volume (2004-2018) 62

5.4.1 Insulin Pens, Volume (2004-2018) 66

5.4.2 Insulin Pumps, Volume (2004-2018) 70

5.5 Insulin Delivery Average Price (2004-2018) 73

5.6 Insulin Delivery Distribution Share (2010-2011) 74

5.7 Insulin Delivery, United States, Company Share (2010-2011) 75

6 Overview of Key Companies in United States Diabetes Care Devices Market 77

6.1 LifeScan, Inc. 77

6.1.1 Company Overview 77

6.1.2 Share in the United States Diabetes Care Devices Market 77

6.2 Medtronic, Inc. 78

6.2.1 Company Overview 78

6.2.2 Share in the United States Diabetes Care Devices Market 78

6.3 Bayer HealthCare AG 79

6.3.1 Company Overview 79

6.3.2 Share in the United States Diabetes Care Devices Market 79

6.4 F. Hoffmann-La Roche Ltd. 80

6.4.1 Company Overview 80

6.4.2 Share in the United States Diabetes Care Devices Market 80

6.5 Abbott Laboratories 81

6.5.1 Company Overview 81

6.5.2 Share in the United States Diabetes Care Devices Market 82

6.6 Becton, Dickinson and Company 83

6.6.1 Company Overview 83

6.6.2 Share in the United States Diabetes Care Devices Market 83

6.7 Eli Lilly and Company 84

6.7.1 Company Overview 84

6.8 Animas Corporation 84

6.8.1 Company Overview 84

6.9 Novo Nordisk A/S 84

6.9.1 Company Overview 84

6.10 Sanofi 85

6.10.1 Company Overview 85

6.11 Insulet Corporation 85

6.11.1 Company Overview 85

6.12 ARKRAY, Inc. 86

6.12.1 Company Overview 86

6.13 B. Braun Melsungen AG 86

6.13.1 Company Overview 86

7 Diabetes Care Devices Market Pipeline Products 87

8 Financial Deals Landscape 93

8.1 Acquisition 93

8.1.1 LifeScan Acquires Calibra Medical 93

8.1.2 Arriva Medical Acquires AmMed Direct For $23 Million 94

8.1.3 ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company 95

8.1.4 DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million 96

8.1.5 Arriva Medical Acquires Direct Diabetic Source 98

8.1.6 Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million 99

8.1.7 Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million 100

8.2 Partnerships 101

8.2.1 Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro Diagnostics 101

8.2.2 Alere Enters Into Co-Development Agreement With AT&T 102

8.2.3 Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS 103

8.2.4 Tethys Bioscience Enters Into Technology Integration Agreement With Lose It 104

8.2.5 Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 105

8.2.6 Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With Helmsley Charitable Trust And Medtronic 106

8.2.7 Tandem Diabetes Enters Into Licensing Agreement With DexCom 107

8.2.8 Roche Diagnostics Enters Into Distribution Agreement With DexCom 108

8.2.9 Roche Diagnostics Enters Into Research And Development Agreement With DexCom 109

8.2.10 Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone 110

9 Recent Developments 111

9.1 Strategy And Business Planning 111

9.1.1 Aug 28, 2012: Medtronic Opens Shanghai Innovation Center 111

9.1.2 Aug 09, 2012: Takeda Establishes Development Center In China 112

9.1.3 Jun 26, 2012: Roche To Shut New Jersey Site, Eliminate 1,000 Jobs 112

9.1.4 May 22, 2012: Greatbatch To Establish New Global Headquarters 113

9.1.5 Mar 21, 2012: HealthMed To Expand Portfolio Of Products Beyond Organ Transplantation 114

9.1.6 Feb 27, 2012: Greatbatch Announces Engagement To Advance Medical Device Strategy 114

9.1.7 Jan 26, 2012: Nipro Diagnostics Purchases New Building, Expands Fort Lauderdale Operations 115

9.1.8 Jan 19, 2012: BD And Mercy/ROi Collaborate To Improve Quality Of Care And Reduce Costs 115

9.1.9 Oct 19, 2011: Abbott To Separate Into Two Leading Companies In Diversified Medical Products And Research-Based Pharmaceuticals 116

9.1.10 Oct 13, 2011: Unisense Establishes US Headquarter 118

9.2 Research And Development 119

9.2.1 Jul 17, 2012: Greatbatch To Establish R&D Centre In Singapore 119

9.2.2 Mar 21, 2012: Index Ventures Launches New €150m Life Sciences Fund With Investments From GSK And Janssen 120

9.2.3 Jan 09, 2012: Bayer HealthCare To Share Lab Space With Start-Up Companies 121

9.3 Legal and Regulatory 122

9.3.1 Jun 29, 2012: Sucampo Pharma Provides Update On Anticipated Arbitration Decision 122

9.3.2 May 30, 2012: Sucampo Announces Change In Date Of Anticipated Arbitration Decision In Dispute With Takeda 122

9.3.3 Apr 17, 2012: Sanmina-SCI Suzhou, China Facility Receives ISO 13485 Certification For Medical Devices 122

9.3.4 Mar 30, 2012: Medtronic Reaches Settlement Of Shareholder Class Action 123

9.3.5 Dec 23, 2011: Glancy Binkow Announces Class Action Lawsuit Against Hospira 123

9.3.6 Dec 13, 2011: Medtronic Reaches Settlement With US Department of Justice 123

9.3.7 Nov 22, 2011: Izard Nobel Announces Class Action Lawsuit Against Hospira 124

9.4 Government and Public Interest 125

9.4.1 Jun 28, 2012: American Diabetes Association Applauds US Supreme Court Decision To Uphold Affordable Care Act 125

9.4.2 Jun 15, 2012: American Diabetes Association Applauds Passage Of Connecticut House Bill 5348 125

9.4.3 Jun 15, 2012: American Diabetes Association Applauds Federal Funding For Diabetes Research And Prevention 126

9.4.4 Jun 15, 2012: OSA Is Associated With Diabetic Peripheral Neuropathy: Study 127

9.4.5 May 23, 2012: Beta Cell Imaging Could Help Spot Diabetes Earlier: Vanderbilt University 128

9.4.6 Mar 13, 2012: Researchers Identify Optimal Threshold For HbA1c Test For Prediabetes 129

9.4.7 Mar 01, 2012: Diabetes Research Institute Develops Revolutionary Oxygen-Generating Biomaterial To Enhance Islet Survival 130

9.4.8 Feb 13, 2012: Blood From Periodontal Disease Can Be Used To Screen For Diabetes: NYU Study 131

9.4.9 Jan 20, 2012: Researchers At Brown University Develops Biochip To Measures Glucose In Saliva 132

9.4.10 Jan 11, 2012: American Diabetes Association Applauds Revised US State Department Policy 133

9.4.11 Jan 03, 2012: Maternal Liver Grafts More Tolerable For Children With Rare Disease: UCSF 133

9.4.12 Oct 14, 2011: MannKind To Present At 18th Annual Newsmakers In BioTech Industry Conference 134

9.4.13 Sep 29, 2011: Research At UC Reveals Hormone Action That Could Lead To Treatments For Type 2 Diabetes 134

9.4.14 Sep 14, 2011: Medtronic Pledges Action In Advance of United Nations High Level Meeting On Noncommunicable Diseases 135

9.5 Product News 136

9.5.1 Oct 28, 2011: ARKRAY's GLUCOCARD Vital And 01 Blood Glucose Meters Are Listed On DoD Uniform Formulary 136

9.5.2 Jun 29, 2010: Medtronic Announces STAR 3 Trial Results Confirming MiniMed Paradigm REAL-Time System Achieves Better Glucose Control Than Daily Insulin Injections In Diabetic Patients 137

9.5.3 Jun 25, 2010: Medtronic Begins Enrollment In ASPIRE Pivotal Study Of MiniMed Paradigm x54 System 138

9.5.4 Mar 17, 2010: Medtronic Announces FDA Approval Of MiniMed Paradigm REAL-Time Revel System 138

9.5.5 Aug 05, 2009: Continuous Glucose Monitoring Benefits Even Well-Controlled Type 1 Diabetics 139

9.5.6 Jul 10, 2009: Medtronic Announces Voluntary Recall Of Paradigm Specific Lots Of Quick-Set Infusion Sets 140

9.5.7 Jun 07, 2009: Medtronic Presents REAL Trend Study Results Of MiniMed Paradigm REAL-Time System At 69th Annual Scientific Sessions Of The ADA 140

9.5.8 May 05, 2009: Bayer HealthCare Releases CONTOUR Meters In Two Bold New Colors, The Midnight Blue And Orange Burst 141

10 Appendix 142

10.1 Definitions of Markets Covered in the Report 143

10.1.1 Diabetes Care Devices 143

10.2 Research Methodology 145

10.3 Secondary Research 145

10.4 Primary Research 146

10.5 Models 146

10.6 Forecasts 147

10.7 Expert Panels 147

10.8 GlobalData Consulting 147

10.9 Currency Conversion 147

10.10 Contact Us 147

10.11 Disclaimer 148

1.1 List of Tables

Table 1: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018 13

Table 2: Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15

Table 3: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018 17

Table 4: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 19

Table 5: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 21

Table 6: Diabetes Care Devices, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 23

Table 7: Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26

Table 8: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 28

Table 9: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 30

Table 10: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 32

Table 11: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 34

Table 12: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011 36

Table 13: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018 38

Table 14: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 40

Table 15: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 42

Table 16: Glucose Monitoring, United States, Average Price ($), Historic, 2004-2011 43

Table 17: Glucose Monitoring, United States, Average Price ($), Forecast, 2011-2018 43

Table 18: Glucose Monitoring, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 44

Table 19: Glucose Monitoring, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 46

Table 20: Insulin Delivery Market, United States, Segment Contribution (%), 2011 49

Table 21: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51

Table 22: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 53

Table 23: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 55

Table 24: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 57

Table 25: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 59

Table 26: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 61

Table 27: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011 63

Table 28: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018 65

Table 29: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 67

Table 30: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 69

Table 31: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 71

Table 32: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 72

Table 33: Insulin Delivery, United States, Average Price ($), Historic, 2004-2011 73

Table 34: Insulin Delivery, United States, Average Price ($), Forecast, 2011-2018 73

Table 35: Insulin Delivery, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 74

Table 36: Insulin Delivery, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 76

Table 37: Diabetes Care Devices Market Pipeline Products 87

Table 38: LifeScan Acquires Calibra Medical 93

Table 39: Arriva Medical Acquires AmMed Direct For $23 Million 94

Table 40: ActiveCare To Acquire 4G Biometrics, Healthcare Technology Company 95

Table 41: DexCom Completes Acquisition Of SweetSpot Diabetes Care For Up To $8.5 Million 96

Table 42: Arriva Medical Acquires Direct Diabetic Source 98

Table 43: Perrigo Acquires CanAm Care, Distributor Of Diabetes Care Products, For $36 Million 99

Table 44: Alere Acquires Arriva Medical From Palm Beach Capital For $83 Million 100

Table 45: Nextgen Healthcare Enters Into Technology Integration Agreement With Nipro Diagnostics 101

Table 46: Alere Enters Into Co-Development Agreement With AT&T 102

Table 47: Telcare Enters Into Licensing Agreement With Diabetech For GlucoDynamix-ADMS 103

Table 48: Tethys Bioscience Enters Into Technology Integration Agreement With Lose It 104

Table 49: Juvenile Diabetes Research Foundation Extends Co-Development Agreement With Becton, Dickinson 105

Table 50: Juvenile Diabetes Research Foundation Enters Into Co-Development Agreement With Helmsley Charitable Trust And Medtronic 106

Table 51: Tandem Diabetes Enters Into Licensing Agreement With DexCom 107

Table 52: Roche Diagnostics Enters Into Distribution Agreement With DexCom 108

Table 53: Roche Diagnostics Enters Into Research And Development Agreement With DexCom 109

Table 54: Pal Health Enters Into Distribution Agreement With Surefit For Xtremityone 110

1.2 List of Figures

Figure 1: Diabetes Care Devices, Market Segmentation 12

Figure 2: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, 2004-2018 13

Figure 3: Diabetes Care Devices Market, United States, Revenue Mix ($m), 2011 14

Figure 4: Diabetes Care Devices Market, United States, Category Contribution (%), 2011 15

Figure 5: Diabetes Care Devices, United States, Cross-Segment Analysis, 2004-2018 16

Figure 6: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 18

Figure 7: Diabetes Care Devices, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 20

Figure 8: Diabetes Care Devices, United States, Company Share (%), 2011 22

Figure 9: Glucose Monitoring, Market Segmentation 24

Figure 10: Glucose Monitoring Market, United States, Revenue Mix ($m), 2011 25

Figure 11: Glucose Monitoring Market, United States, Segment Contribution (%), 2011 26

Figure 12: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 27

Figure 13: Glucose Monitoring, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 29

Figure 14: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 31

Figure 15: Blood Glucose Meters, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 33

Figure 16: Glucose Monitoring, United States, Volume (Units) by Segment, Historic, 2004-2011 35

Figure 17: Glucose Monitoring, United States, Volume (Units) by Segment, Forecast, 2011-2018 37

Figure 18: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 39

Figure 19: Blood Glucose Meters, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 41

Figure 20: Glucose Monitoring, United States, Company Share (%), 2011 45

Figure 21: Insulin Delivery, Market Segmentation 47

Figure 22: Insulin Delivery Market, United States, Revenue Mix ($m), 2011 48

Figure 23: Insulin Delivery Market, United States, Segment Contribution (%), 2011 49

Figure 24: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 50

Figure 25: Insulin Delivery, United States, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 52

Figure 26: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 54

Figure 27: Insulin Pens, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 56

Figure 28: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 58

Figure 29: Insulin Pumps, United States, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 60

Figure 30: Insulin Delivery, United States, Volume (Units) by Segment, Historic, 2004-2011 62

Figure 31: Insulin Delivery, United States, Volume (Units) by Segment, Forecast, 2011-2018 64

Figure 32: Insulin Pens, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 66

Figure 33: Insulin Pens, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 68

Figure 34: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Historic, 2004-2011 70

Figure 35: Insulin Pumps, United States, Volume (Units) by Sub-Segment, Forecast, 2011-2018 72

Figure 36: Insulin Delivery, United States, Company Share (%), 2011 75

Figure 37: LifeScan, Inc., Company Share (%),United States Diabetes Care Devices Market, 2011 77

Figure 38: Medtronic, Inc., Company Share (%),United States Diabetes Care Devices Market, 2011 78

Figure 39: Bayer HealthCare AG, Company Share (%),United States Diabetes Care Devices Market, 2011 79

Figure 40: F. Hoffmann-La Roche Ltd., Company Share (%),United States Diabetes Care Devices Market, 2011 80

Figure 41: Abbott Laboratories, Company Share (%),United States Diabetes Care Devices Market, 2011 82

Figure 42: Becton, Dickinson and Company, Company Share (%),United States Diabetes Care Devices Market, 2011 83

Companies mentioned

LifeScan, Inc.

Medtronic, Inc.

Bayer HealthCare AG

F. Hoffmann-La Roche Ltd.

Abbott Laboratories

Becton, Dickinson and Company

Eli Lilly and Company

Animas Corporation

Novo Nordisk A/S

Sanofi

Insulet Corporation

ARKRAY, Inc.

B. Braun Melsungen AG

To order this report:

Pathology Industry: United States Diabetes Care Devices Market Outlook to 2018- Glucose Monitoring and Insulin Delivery

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker